GET DAILY SIGNALSImmunityBio (IBRX) Falls -38.7% in 30 Days After Earnings Miss and Going-Concern Note
Key Takeaways
- IBRX shares fell roughly 38.7% in the 30 days through the close on November 12, 2026, dropping from $9.91 to $6.07.
- The primary catalyst was a third-quarter 2026 report that missed Wall Street's revenue and earnings-per-share estimates.
- ANKTIVA net product revenue rose 53% year over year to $48.7 million but declined about 4% sequentially, ending eight consecutive quarters of growth.
- A sharply wider net loss and a going-concern disclosure renewed investor concerns about funding and potential dilution.
- Positive clinical and regulatory updates were overshadowed by the financial results, including the QUILT-2.005 trial meeting its primary endpoint, an October 14 FDA label expansion, and a new approval in Israel.
- Over the broader quarter, the stock is down approximately 20.7% from its August 13 closing level of $7.65.
ImmunityBio and Its Place in Immunotherapy
ImmunityBio, Inc. (IBRX) is a commercial-stage immunotherapy company focused on activating the immune system to treat cancer and infectious diseases. Its platform centers on ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist antibody-cytokine fusion protein that stimulates natural killer cells, cytotoxic T cells, and memory T cells. ANKTIVA is approved for BCG-unresponsive non-muscle invasive bladder cancer, and the company is pursuing label expansions into earlier lines of treatment. ImmunityBio also maintains a pipeline spanning vaccine vectors and NK-cell therapies. I follow IBRX closely because it pairs an approved, commercialized product with a clinical program that could meaningfully expand its addressable patient population. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
IBRX Stock Price Performance Over the Past 30 Days and Quarter
Over the most recent 30-day period, IBRX declined from a closing price of $9.91 on October 14, 2026, to $6.07 on November 12, 2026, a drop of approximately 38.7%. The decline accelerated after the company's third-quarter earnings release on November 9, when the stock fell roughly 15% to more than 25% intraday before continuing lower in subsequent sessions. The quarterly picture is more mixed. From an August 13 close of $7.65, the stock first rallied into early October, touching a closing high near $10.51 on October 9 before reversing. By November 12 the shares had fallen to $6.07, leaving the stock down about 20.7% over the roughly three-month span. The pattern reflects a momentum-driven run-up into positive catalysts, followed by a sharp repricing once earnings and liquidity concerns reasserted themselves.
What Drove the Recent Move in IBRX
The dominant driver was the November 9 third-quarter earnings release. Total revenue rose roughly 52% to 53% year over year to $48.8 million, but came in well below consensus estimates that ranged near $59 million to $61 million. Net product revenue of $48.7 million declined about 4% sequentially, interrupting a streak of eight consecutive quarters of growth and raising questions about the pace of ANKTIVA adoption among U.S. urologists. The bottom line compounded the concern. Net loss attributable to shareholders widened to $184.6 million from $67.3 million a year earlier, driven in part by a roughly $77.9 million non-cash charge tied to fair-value changes on a related-party convertible note, warrants, and derivative liabilities, alongside higher R&D and selling expenses. Adjusted losses also missed expectations. Adding to the pressure, the company's quarterly filing repeated language stating that substantial doubt exists about its ability to continue as a going concern without additional funding, and management noted roughly $334.3 million in cash and marketable securities at September 30. Those funding and dilution dynamics weighed on sentiment even as the stock traded at a valuation of around 39 times annualized sales. From what I see, the liquidity discussion is the element that has investors most on edge right now.
Clinical Momentum Versus Financial Fundamentals Over the Quarter
The quarterly trend was shaped by a tug-of-war between clinical momentum and financial fundamentals. Entering the period, IBRX had already more than tripled from its level at the end of 2025, supported by ANKTIVA's commercial ramp and a series of regulatory catalysts. In October, the FDA expanded ANKTIVA's label to include high-grade papillary-only tumors that no longer respond to BCG, and the company announced that ANKTIVA plus BCG met the primary endpoint in the QUILT-2.005 trial in previously untreated NMIBC patients, with Israel granting approval and bringing total authorizations to 35 countries. Those developments fueled the run-up toward the early-October highs. However, the third-quarter financial update reset expectations, as the revenue shortfall, sequential sales decline, widening loss, and reiterated going-concern language prompted investors to reassess the stock's premium valuation and the pace of cash consumption relative to commercial progress. I’m watching this closely because the balance between pipeline progress and cash runway will likely dictate near-term sentiment.
Key Factors to Monitor Ahead
Going forward, investors are likely to monitor ANKTIVA's sales trajectory to see whether the sequential dip proves temporary or signals slowing adoption. Management's planned supplemental FDA submission for ANKTIVA in previously untreated NMIBC patients remains a key catalyst, as a broader label could expand the eligible patient pool. Funding and dilution remain central themes, with attention on cash balances, operating cash burn, and any equity issuance or support from affiliated parties. Macroeconomic conditions and small-cap biotech sentiment may also influence trading. Finally, updates on additional global approvals and pipeline programs will help shape the longer-term outlook, though none of this constitutes investment advice or a prediction of future performance.
Using AI Tools in My Research Process
When I want a data-driven view of how different strategies are behaving around names like IBRX, I often look at Tickeron’s AI Trading Bots. The platform lets me review curated, top-performing automated approaches across various timeframes and risk profiles, which helps me compare options without committing to any single method. It serves as a practical reference point alongside my own fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IBRX in downward trend: 10-day moving average crossed below 50-day moving average on October 28, 2026
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 81 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 47 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for IBRX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.498). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement